EP0129258B1 - Imidazoquinazoline compound - Google Patents

Imidazoquinazoline compound Download PDF

Info

Publication number
EP0129258B1
EP0129258B1 EP84107130A EP84107130A EP0129258B1 EP 0129258 B1 EP0129258 B1 EP 0129258B1 EP 84107130 A EP84107130 A EP 84107130A EP 84107130 A EP84107130 A EP 84107130A EP 0129258 B1 EP0129258 B1 EP 0129258B1
Authority
EP
European Patent Office
Prior art keywords
compound
test
piperidino
formula
tetrahydroimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP84107130A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0129258A1 (en
Inventor
Fumiyoshi C/O Daiichi Seiyaku Res.Lab. Ishikawa
Shinichiro C/O Daiichi Seiyaku Res.Lab. Ashida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to AT84107130T priority Critical patent/ATE29884T1/de
Publication of EP0129258A1 publication Critical patent/EP0129258A1/en
Application granted granted Critical
Publication of EP0129258B1 publication Critical patent/EP0129258B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to a novel compound having a blood platelet aggregation inhibitory activity and a salt thereof. More particularly, this invention relates to 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one of the formula (I): and a pharmaceutically acceptable salt thereof.
  • Known compounds having the same skeleton as the compound of the above-described formula (I) include antihypertensive compounds represented by the formula (II): wherein R 1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms; n represents 1 or 2; and R 2 and R 3 and R 3 , being different from each other, each represents a hydrogen atom, a chlorine atom, a bromine atom, a fluorine atom, a fluoromethyl group, a sulfonic acid group, a hydroxyl group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a nitro group, an amino group; or a phenyl group; or R 2 and R 3 , being the same, each represents a hydrogen atom, a chlorine atom, a bromine atom, a fluorine atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms or an alk
  • Patent 3,932,407 corresponding to Japanese Patent Publication No. 23994/81.
  • the above-mentioned U.S. Patent reported that these compouinds exhibit a blood platelet aggregation inhibitory activity in addition to the antihypertensive activity.
  • U.S. Patent 4,256,748 discloses imidazo[2,1-b]quinazoiin-2(3H)-ones which are useful for treating and prophylaxis of cardiac insufficiency and cardiac failure, but these compounds have a substituent such as an alkyl group at the 3-position of the imidazo[2,1-b]quinazolin skeleton and their activity is different from that of the compound of this invention.
  • the inventors have conducted extensive studies to eliminate the above-described disadvantages possessed by the known compounds (11), i.e., sparing water-solubility and the adverse influence on the circuIatory system, and, as a result, found that the compound represented by the formula (I) is easily soluble in water to exhibit high activity even through parenteral administration and also has but relatively slight influence on the circulatory system while retaining a potent platelet aggregation inhibitory activity, when compared with the above-described compounds (II). It was also found that the compound (I) of the present invention possesses an activity to inhibit metastasis of cancers and an activity to protect against > stress-induced gastric ulceration and to stimulate secretion of pancreatic juice and bicarbonates.
  • the compound represented by the formula (I) may be present in the form of tautomers as shown by the following formulae (la) and (lb), but it should be understood that they are also included in the scope of the ; invention.
  • Patent 3,932,407 and 7-amino-1,2,3,5-tetrahydro- imidazo[2,1-b]quinazolin-2-one dihydrochloride (BL-7-NH 2 ) which has a similar basic residue as that of the compound (I) and is also described in the same U.S. Patent.
  • the compound of the present invention is highly watersoluble and also has a sufficient solubility even in water having a pH value used for parenteral preparations in view of the potency of anti-platelet aggregation activity hereinafter described. Therefore, the compound of the present invention is superior to the known compounds (BL-3459 & BL-4162) in terms of water solubility.
  • test was performed as follows in accordance with the method of Ashida et al, Thrombosis and Haemostasis, Vol. 40, p. 542 (1979).
  • Plasma samples were taken by puncture from the heart of a Wistar Imamichi rat under anesthesia with pentobarbital into a syringe containing 1/10 volume of a 3.13% aqueous solution of sodium citrate dihydrate, and the citrated blood was centrifuged to obtain a platelet-rich-plasma (PRP).
  • PRP platelet-rich-plasma
  • citrated blood was collected from the vein of a healthy human who had not taken aspirin or any other anti-inflammatory agent since before 10 days, followed by centrifugation to obtain PRP.
  • 0.005 ml of each test compound was added to 0.445 ml each of these PRP samples, and the system was warmed at 30°C for 1 minute.
  • the compound of the present invention exhibits anti-platelet aggregation activity substantially equal to that of BL-3459 and BL-4162 which had been reported to have potent activity.
  • BL-7-NH 2 having a basic residue scarcely exhibits platelet aggregation inhibitory activity.
  • test compound was dissolved or suspended in a 0.5% Tween 80 aqueous solution and orally administered to 5 male Wistar Imamichi rats (body weight: about 270 g) per group which had been fasted overnight at a dose of 10 mg/Kg or 1.0 mg/Kg.
  • body weight about 270 g
  • citrated blood was taken from the heart, and platelet aggregation was determined in the same manner as described in Test Example 2. The results obtained are shown in Table 3.
  • the compound of the present invention showed a significant aggregation inhibitory activity in either ADP- or collagen-induced aggregation at a dose level either of 10 mg/Kg or 1 mg/Kg, whereas the activity of the comparative compounds (BL-3459 & BL-4162), though somewhat displayed, widely varied depending on the individual animal and, therefore, cannot be regarded significant. This proves that the compound of the present invention produces a reliable effect when orally administered to animals.
  • test animals 5 male Wistar-Imamichi rats (body weight: about 270 g) that had been allowed food and water ad libitum were used per group.
  • the test compound was dissolved in a physiological saline physiological saline solution (J.P.) and continuously injected to the rats under anesthesia with pentobarbital through the femoral vein. 15 minutes later, citrated blood was taken from the heart, and platelet aggregation was determined in the same manner as in Test Example 2. The results are shown in Table 4 below.
  • the compound of the present invention possesses a sure and significant activity to inhibit platelet aggregation at extremely low doses. This can be one of and the greatest of excellent characteristics of the compound of the present invention from the fact that many compounds having platelet aggregation inhibitory activity are known but none of them exerts such kind of platelet aggregation inhibitory activity through intravenous administration.
  • Blood was taken from the abdominal vein of a 7-week-old C57BU6 male mouse into a syringe containing 1/10 volume of a 3.13% aqueous solution of sodium citrate dihydrate as an anticoagulant.
  • the thus prepared citrated blood sample was centrifuged at 230 x g at room temperature for 7 minutes.
  • the resulting supernatant fluid was used as PRP.
  • the remainder was further centrifuged at 1,500 x g at room temperature for 10 minutes, and the supernatant fluid was used as platelet-poor-plasma (PPP). Platelet count in PRP was adjusted to 450,000 per mm 3 by PPP.
  • a 450 ⁇ ml of PRP was placed in a reaction tube and subjected to centrifugation at 950 rpm at 30°C. About 1 minute later while continuing the centrifugation, 5 ⁇ l of a 200 mM calcium chloride aqueous solution was added to the system to a final concentration of 2 pM.
  • the compound of the invention (dihydrochloride monohydrate) dissolved in a physiological saline solution (J.P.) was intravenously or orally administered to a 7-week-old C57BU6 male mouse (body weight: about 20 g).
  • a physiological saline solution J.P.
  • blood was taken from the abdominal vein into a syringe containing 1/10 volume of a 3.13% aqueous solution of sodium citrate dihydrate and PRP was prepared as described before in Test Example 6.
  • the PRP was placed in a reaction tube under the same conditions as in Test Example 6, and 5 ⁇ l of a 200 mM calcium chloride aqueous solution was added thereto.
  • the B16BL6-induced aggregation was completely inhibited by the compound of the present invention at a level of 1 mg/kg or more irrespective of the administration route.
  • the 3LL-induced aggregation was delayed 150% or more with 10 mg/kg (i.v.) of the compound of the invention and completely inhibited with 30 mg/kg (i.v.) of the compound of the invention.
  • the compound of the present invention (dihydrochloride monohydrate) was dissolved in a physiological saline solution (J.P.) and intravenously administered to the tail vein of a 5-week-old C57BU6 male mouse (body weight: about 18.5 g) at a dose of 10 mg/kg or 30 mg/kg. After 3 minutes, 5 x 10 5 cells of B16BL6 were intravenously inoculated to the tail vein. The death ratios 3 and 10 minutes after the inoculation are shown in Table 6.
  • the compound of the present invention demonstrated an effect to inhibit metastasis of cancers, which effect being ascribed to inhibition on embolus and thrombus formation in the lungs.
  • a metastasis inhibitory activity can be exercised with therapeutic effects when applied to, for example, patients with cancer, before or after operation, in which hematogeneous metastasis is predicted and patients with cancer in which consumptive reduction of platelets and fibrinogen is observed but there is no tendency of hemorrhage.
  • the LD 50 values of the compound of the present invention as determined by the probit method are as shown in Table 8.
  • Compound (I) of this invention did not show any significant activity on the pancreatic juice secretion at a dose of 100 pg/kg (i.v.), whereas, at a dose of 300 ⁇ g/kg (i.v.), it increased the secretion to a degree of 214% after 15 minutes and, at a dose of 1000 pg/kg (i.v.), it exhibited significant increases in the secretion to a degree of 440% (after 15 minutes) and 202% (after 30 minutes), as compared with the control (100%).
  • Compound (I) exhibited an increase to 161 % at a dose of 300 pg/Kg (i.v.) and a significant increase to 254% at a dose of 1000 pg/Kg (i.v.), as compared with the control (100%).
  • Compound (I) increased the bicarbonate ion concentration in pancreatic juice to 109% at a dose of 100 pg/Kg (i.v.), 130% at a dose of 300 ⁇ g/Kg (i.v.) and 266% at a dose of 1000 ug/Kg, as compared with the control, respectively, and the increases at 300 and 1000 were considered significant.
  • Compound (I) exhibited increases to 116% at a dose of 100 pg/Kg (i.v.), 198% at a dose of 300 pg/Kg and 674% at a dose of 1000 pg/Kg, as compared with the control, respectively, and the increases at 300 and 1000 ug/Kg were considered significant.
  • Donryu male rats having a body weight of 352 to 414 g were subjected to the stress-induced gastric ulceration test by water-immersion and immobilization [Takagi and Okabe, Japan J. Pharmacol., 18, 9-18 (1968)] at a water temperature of 20 to 22°C for 7 hours.
  • Compound (I) was administered orally in the form of a suspension in a 0.5% aqueous CMC solution at a dose of 5 ml/Kg 30 minutes before loading the stress. After the test period, the rats were sacrificed and the hyperemic area and the erosious area on the stomach inside wall were measured to determine % inhibition of the ulcer. The results obtained are shown in Table 11 below.
  • the compound (I) is produced by reacting a compound represented by the formula (III): wherein R represents a lower alkyl group having 1 to 6 carbon atoms, and X represents a halogen atom, e.g., CI, Br, with ammonia.
  • the reaction is advantageously carried out in a sealed tube in the presence of a solvent such as a lower alcohol, e.g., methanol or ethanol, at a temperature of from about 100°C to about 150°C.
  • a solvent such as a lower alcohol, e.g., methanol or ethanol
  • the compound of the present invention is also prepared by reacting a compound represented by the formula (IV): wherein R represents a lower alkyl group having 1 to 6 carbon atoms, with a cyanogen halide, such as cyanogen bromide, or N-amidinopyrazole.
  • a cyanogen halide such as cyanogen bromide, or N-amidinopyrazole.
  • the above reaction is advantageously carried out in a solvent such as a lower alcohol, e.g., methanol or ethanol, under reflux or at room temperature followed by treating the reaction mixture with a weak base such as sodium bicarbonate or sodium carbonate.
  • a solvent such as a lower alcohol, e.g., methanol or ethanol
  • a weak base such as sodium bicarbonate or sodium carbonate.
  • the compound of the formula (I) thus obtained can be converted into its pharmaceutically acceptable salts with organic or inorganic acids, if necessary.
  • Such salts include a hydrochloride, a hydrobromide, a sulfate, a phosphate, an alkyl- or arylsulfonate, a fumarate, a maleate, a succinate, a citrate and other salts formed with acids commonly employed in the art, with hydrochloride being preferred.
  • these compounds can be formulated into pharmaceutical compositions together with ordinary pharmaceutically acceptable carriers selected depending on the type of dosage forms.
  • Suitable carriers which can be used are, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, calcium hydrogenphosphate, talc, vegetable oils or polyalkylene glycols.
  • Typical dosage forms of the therapeutic agents can be selected according to the purpose of the therapy.
  • Typical dosage forms which can be used include tablets, capsules, powders, liquid preparations, suspensions and injectable preparations (solutions, suspensions, etc.).
  • the compound of this invention and its pharmaceutically acceptable salts can preferably be administered orally or through intravenous injection.
  • the dosage of the compound is usually about 1 mg to 20 mg per adult human per day in oral administration or about 0.1 mg to 10 mg per adult human per day in intravenous administration.
  • the resulting product was added to 100 ml of a 10% ethanol solution of ammonia, and the mixture was heated in a sealed tube at 120°C to 130°C for 4 hours. After cooling, the precipitated crystals were filtered, washed with water and dried to obtain 13.0 g of 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one as a free base.
  • This product was suspended in methanol, and concentrated hydrochloric acid was added thereto to adjust to a pH of 1 to 2 thereby forming a solution. The solution was then treated with charcoal, followed by fltration, and the filtrate was concentrated under reduced pressure. The precipitated crystals were collected to give a dihydrochloride monohydrate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Furan Compounds (AREA)
EP84107130A 1983-06-21 1984-06-20 Imidazoquinazoline compound Expired EP0129258B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT84107130T ATE29884T1 (de) 1983-06-21 1984-06-20 Imidazochinazolinverbindung.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58111498A JPS604186A (ja) 1983-06-21 1983-06-21 イミダゾキナゾリン化合物
JP111498/83 1983-06-21

Publications (2)

Publication Number Publication Date
EP0129258A1 EP0129258A1 (en) 1984-12-27
EP0129258B1 true EP0129258B1 (en) 1987-09-23

Family

ID=14562811

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84107130A Expired EP0129258B1 (en) 1983-06-21 1984-06-20 Imidazoquinazoline compound

Country Status (19)

Country Link
US (1) US4596806A (es)
EP (1) EP0129258B1 (es)
JP (1) JPS604186A (es)
KR (1) KR910003153B1 (es)
AT (1) ATE29884T1 (es)
AU (1) AU558124B2 (es)
CA (1) CA1231946A (es)
DE (1) DE3466392D1 (es)
DK (1) DK162999C (es)
ES (1) ES533609A0 (es)
FI (1) FI77864C (es)
GR (1) GR81629B (es)
IE (1) IE57736B1 (es)
IL (1) IL72188A (es)
NO (1) NO161220C (es)
PH (1) PH19413A (es)
PT (1) PT78775A (es)
YU (1) YU43576B (es)
ZA (1) ZA844437B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663320A (en) * 1983-02-16 1987-05-05 Syntex (U.S.A.) Inc. (2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinoazolinyl)oxyalkylamides, compositions and the use thereof
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
IL74349A (en) * 1984-02-15 1988-07-31 Syntex Inc (2-oxo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolinyl)-oxyalkylamides,their preparation and pharmaceutical compositions containing them
US4783467A (en) * 1985-06-05 1988-11-08 Pfizer Inc. Tetrahydroimidazoquinazolinone inotropic agents
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4670434A (en) * 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4766126A (en) * 1986-01-10 1988-08-23 Daiichi Seiyaku Co., Ltd. Process for treatment of nephritis with imidazoquinazolines
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system

Also Published As

Publication number Publication date
DK162999B (da) 1992-01-06
FI842532A0 (fi) 1984-06-21
GR81629B (es) 1984-12-11
IE57736B1 (en) 1993-03-24
FI77864B (fi) 1989-01-31
FI842532A (fi) 1984-12-22
IL72188A0 (en) 1984-10-31
PT78775A (en) 1984-07-01
ATE29884T1 (de) 1987-10-15
NO161220B (no) 1989-04-10
JPS604186A (ja) 1985-01-10
YU43576B (en) 1989-08-31
DE3466392D1 (de) 1987-10-29
JPS635030B2 (es) 1988-02-01
ES8603483A1 (es) 1985-12-16
DK162999C (da) 1992-06-01
FI77864C (fi) 1989-05-10
ES533609A0 (es) 1985-12-16
US4596806A (en) 1986-06-24
EP0129258A1 (en) 1984-12-27
KR910003153B1 (ko) 1991-05-20
AU558124B2 (en) 1987-01-22
AU2943284A (en) 1985-01-03
IL72188A (en) 1987-03-31
DK290084A (da) 1984-12-22
PH19413A (en) 1986-04-10
YU107884A (en) 1986-10-31
DK290084D0 (da) 1984-06-13
ZA844437B (en) 1985-01-30
NO161220C (no) 1989-07-19
KR850000442A (ko) 1985-02-27
CA1231946A (en) 1988-01-26
IE841549L (en) 1984-12-21
NO842502L (no) 1984-12-27

Similar Documents

Publication Publication Date Title
SU1349700A3 (ru) Способ получени (2-оксо-1,2,3,5-тетрагидроимидазо-/2,1- @ /хиназолинил)оксиалкиламидов,их оптических изомеров или фармакологически приемлемых солей с кислотами
EP0133234B1 (en) Imidazoquinazolin-2-one compounds process for their production and pharmaceutical compositions containing said compounds
IE47798B1 (en) Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents
BG60428B2 (bg) Бензимидазоли,метод за получаването им и лекарствени средства, които ги съдържат
RU2233278C2 (ru) Пиримидиновые соединения, способ их получения и фармацевтическая композиция
EP0129258B1 (en) Imidazoquinazoline compound
IE840655L (en) 1,3-thiazolidine derivatives
UA64714C2 (en) Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases
US4182887A (en) 3-Amino-4-phenyl-1H-pyrazolo[3,4-b]pyridines and salts thereof
PL151696B1 (en) Method of obtaining derivatives of quinolone
US4609659A (en) 2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy
EP0429464B1 (en) Bivalent ligands effective for blocking acat enzyme
EP0161498B1 (en) Phenylpiperazine derivatives and their acid addition salts
US3792057A (en) Substituted indenoimidazoles
US4029780A (en) 3-Piperazinyl 1,2,4-benzothiadiazine 1,1-dioxide derivatives their compositions and method of use
US4183934A (en) 4-Hydroxy-7-(substituted)phenylpteridines
EA003511B1 (ru) Производные пиперазинона и их применение
US4416882A (en) Di(alkylamino) derivatives of chloronitropyrazines useful as adjuncts to radiation therapy
US4203983A (en) Spasmolytic triazinones
IE51727B1 (en) Pyridine derivatives as immunoregulatory agents
US3651230A (en) Compositions and methods for tranquilizing with substituted 3-phenyl-4-quinazolinone derivatives
AU631801C (en) Bivalent ligands effective for blocking acat enzyme
US4709035A (en) 2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy
EP0111151A1 (en) Substituted nitropyrazine compounds, process for their preparation and pharmaceutical compositions containing them
FR2640975A1 (es)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19850325

17Q First examination report despatched

Effective date: 19861023

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 29884

Country of ref document: AT

Date of ref document: 19871015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3466392

Country of ref document: DE

Date of ref document: 19871029

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITPR It: changes in ownership of a european patent

Owner name: CAMBIO RAGIONE SOCIALE;DAIICHI PHARMACEUTICAL CO.,

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19930430

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19930510

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19930603

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19930608

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19930614

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19930629

Year of fee payment: 10

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19930630

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930831

Year of fee payment: 10

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: DAIICHI PHARMACEUTICAL CO., LTD. TE TOKIO, JAPAN.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19940620

Ref country code: AT

Effective date: 19940620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19940621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940630

Ref country code: CH

Effective date: 19940630

Ref country code: BE

Effective date: 19940630

BERE Be: lapsed

Owner name: DAIICHI SEIYAKU CO. LTD.

Effective date: 19940630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19950101

EUG Se: european patent has lapsed

Ref document number: 84107130.1

Effective date: 19950110

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940620

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19950228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19950301

EUG Se: european patent has lapsed

Ref document number: 84107130.1

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST